Highlights
- CSL Limited (ASX:CSL) reported FY26 Operating Revenue of US$15.797 billion.
- The group recorded a US$2.579 billion net loss attributable to shareholders.
- FY26 Operating Cash Flow reached approximately US$3.5 billion.
- FY27 guidance indicates broadly unchanged revenue and approximately 5% underlying NPAT growth.
CSL Limited develops and manufactures plasma-derived medicines, influenza vaccines and treatments for iron deficiency and kidney disorders through its international biotechnology operations. On November 17, 2026, shares in CSL Limited (ASX:CSL) traded at AUD 198.93, a decline of 1.77% during the session. The company is progressing operational changes after recording a statutory loss in FY26, while its FY27 guidance outlines different revenue trajectories for its Behring, Seqirus and Vifor businesses.
Three Businesses Serving Different Medical Needs
CSL Behring supplies plasma-derived and recombinant therapies for conditions including immune deficiencies, bleeding disorders and hereditary angioedema. Its operations depend on plasma collection, processing capacity, Manufacturing yields and the distribution of specialist medicines. The Business also markets newer therapies, including ANDEMBRY and HEMGENIX, within its broader portfolio.
CSL Seqirus develops and supplies influenza vaccines, including seasonal products and Pandemic preparedness services. CSL Vifor focuses on iron deficiency and kidney-related treatments. Together, the segments give CSL (ASX:CSL) exposure to distinct medical markets, each with its own product demand, regulatory requirements and competitive conditions. The group operates manufacturing, research and commercial facilities across international markets.
Transformation Measures and 2026 Developments
In its August 2026 full-year release, CSL reported approximately US$176 million in savings from its transformation programme. The measures included simplifying fixed infrastructure and combining certain Behring and Vifor commercial and medical activities. The company said some savings were being reinvested in commercial capabilities and development programmes, alongside work on plasma productivity and manufacturing efficiency.
During 2026, CSL (ASX:CSL) also outlined a US$1.5 billion expansion of plasma therapy manufacturing capacity at Kankakee, Illinois. In late August, it announced agreements with U.S. government agencies concerning Medicaid medicine pricing and domestic manufacturing investment. CSL stated that the arrangements were not expected to have a material financial effect in FY27.
FY26 Earnings, Cash Generation and Segment Trends
For the year ended June 30, 2026, CSL reported revenue of US$15.797 billion, compared with US$15.558 billion a year earlier at reported exchange rates. Its underlying net profit after tax before amortisation, attributable to shareholders, was US$3.098 billion. The statutory result was a US$2.579 billion loss attributable to shareholders, following restructuring and Impairment charges. Operating cash flow was approximately US$3.5 billion, and the final Dividend was maintained at US$1.62 per share.
The FY26 accounts recorded US$7.923 billion in restructuring and impairment expenses, including significant impairment-related charges. The difference between underlying Earnings and the statutory result is therefore relevant when interpreting the group’s annual performance. Cash generation remained positive, although non-recurring expenses materially affected reported profitability.
CSL Behring contributed US$11.387 billion in segment revenue, CSL Vifor US$2.379 billion and CSL Seqirus US$2.031 billion. On a constant-currency basis, their revenue movements were declines of 1% and 8% for Behring and Seqirus, respectively, and a 3% increase for Vifor. Immunoglobulin inventory normalisation, iron-product competition and influenza market conditions contributed to the differing segment outcomes.
FY27 Guidance and Industry Considerations
At FY26 exchange rates, CSL expects FY27 group revenue to be broadly unchanged and underlying net profit after tax to increase by approximately 5%. CSL Behring anticipates mid-single-digit revenue growth, including mid-to-high-single-digit immunoglobulin growth. CSL Seqirus expects low-single-digit growth, with U.S. influenza immunisation rates expected to remain under pressure.
CSL Vifor expects revenue to fall by approximately 25%, reflecting generic competition in iron therapies, the end of a reimbursement-related period for VELPHORO and the Withdrawal of European Marketing authorisation for TAVNEOS. For CSL (ASX:CSL), the extent to which Behring and Seqirus progress against their forecasts will be considered alongside this expected Vifor contraction.
Risks and What to Watch Next
The business remains exposed to pharmaceutical pricing policies, regulatory decisions, generic competition and changes in vaccination uptake. Plasma collection efficiency, manufacturing costs and the timing of capacity expansion are additional operational considerations. Transformation projects also involve execution and spending requirements, while Vifor faces explicitly identified product-level pressures.
The next financial reporting periods will provide evidence of progress on guidance, transformation savings and cash generation. For CSL (ASX:CSL), reported immunoglobulin sales, Seqirus Vaccine demand, Vifor revenue and updates on the Kankakee expansion are among the specific measures to monitor.
Key Insights
CSL enters FY27 with ongoing changes to its operating model, significant FY26 statutory charges and different expectations across its three divisions. Its US$3.5 billion operating cash flow contrasts with its reported loss, while management anticipates broadly flat revenue and approximately 5% Underlying Profit growth. Future disclosures will indicate how production measures, Vifor competition and capital Investment affect the company’s operating position.






Please wait processing your request...